Correspondence 0001193125-24-156046 from Prelude Therapeutics Inc (PRLD) (CIK 0001678660) (PRLD)
Prelude Therapeutics Inc (PRLD) (CIK 0001678660)
Date: June 6, 2024 · CIK: 0001678660 · Accession: 0001193125-24-156046
AI Filing Summary & Sentiment
File numbers found in text: 333-279829
Letter
Re: Prelude Therapeutics Incorporated
June 6, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Office of Life Sciences
Registration Statement on Form S-3
Filed May 30, 2024
File No. 333-279829
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Prelude Therapeutics Incorporated (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement, as amended, so that such registration statement may become effective at 4:30 p.m. (Washington, D.C. time) on June 10, 2024, or as soon as practicable thereafter.
PRELUDE THERAPEUTICS INCORPORATED
By:
/s/ Bryant D. Lim
Name:
Bryant D. Lim
Title:
Chief Legal Officer, Secretary & Interim Chief Financial Officer
cc: Richard B. Aldridge, Morgan, Lewis & Bockius LLP
Bryan S. Keighery, Morgan, Lewis & Bockius LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP June 6, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Office of Life Sciences Re: Prelude Therapeutics Incorporated Registration Statement on Form S-3 Filed May 30, 2024 File No. 333-279829 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Prelude Therapeutics Incorporated (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement, as amended, so that such registration statement may become effective at 4:30 p.m. (Washington, D.C. time) on June 10, 2024, or as soon as practicable thereafter. PRELUDE THERAPEUTICS INCORPORATED By: /s/ Bryant D. Lim Name: Bryant D. Lim Title: Chief Legal Officer, Secretary & Interim Chief Financial Officer cc: Richard B. Aldridge, Morgan, Lewis & Bockius LLP Bryan S. Keighery, Morgan, Lewis & Bockius LLP